{"id":"https://openalex.org/W7225618145","doi":"https://doi.org/10.3389/fphar.2026.1931140","title":"Bevacizumab in first-line postoperative treatment of advanced ovarian cancer: from high-risk stratification to precision decision-making","display_name":"Bevacizumab in first-line postoperative treatment of advanced ovarian cancer: from high-risk stratification to precision decision-making","publication_year":2026,"publication_date":"2026-11-09","ids":{"openalex":"https://openalex.org/W7225618145","doi":"https://doi.org/10.3389/fphar.2026.1931140"},"language":"en","primary_location":{"id":"doi:10.3389/fphar.2026.1931140","doi":"https://doi.org/10.3389/fphar.2026.1931140","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1931140","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1931140/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1931140/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005758811","display_name":"Lan Zhong","orcid":"https://orcid.org/0000-0002-4035-6285","observed_orcids":["https://orcid.org/0000-0002-4035-6285"]},"institutions":[{"id":"https://openalex.org/I24185976","display_name":"Sichuan University","ror":"https://ror.org/011ashp19","country_code":"CN","type":"education","lineage":["https://openalex.org/I24185976"]},{"id":"https://openalex.org/I4210089228","display_name":"West China Second University Hospital of Sichuan University","ror":"https://ror.org/00726et14","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210089228"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Lan Zhong","raw_affiliation_strings":["Department of Medical Oncology, West China Second University Hospital, Sichuan University","Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, West China Second University Hospital, Sichuan University","institution_ids":["https://openalex.org/I24185976","https://openalex.org/I4210089228"]},{"raw_affiliation_string":"Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education","institution_ids":["https://openalex.org/I24185976"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5134332402","display_name":"Liang Song","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I24185976","display_name":"Sichuan University","ror":"https://ror.org/011ashp19","country_code":"CN","type":"education","lineage":["https://openalex.org/I24185976"]},{"id":"https://openalex.org/I4210089228","display_name":"West China Second University Hospital of Sichuan University","ror":"https://ror.org/00726et14","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210089228"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Liang Song","raw_affiliation_strings":["Department of Medical Oncology, West China Second University Hospital, Sichuan University","Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, West China Second University Hospital, Sichuan University","institution_ids":["https://openalex.org/I24185976","https://openalex.org/I4210089228"]},{"raw_affiliation_string":"Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education","institution_ids":["https://openalex.org/I24185976"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5134332402"],"corresponding_institution_ids":["https://openalex.org/I24185976","https://openalex.org/I4210089228"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.9613999724388123,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.9613999724388123,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.03669999912381172,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":1.0},{"id":"https://openalex.org/keywords/advanced-epithelial-ovarian-cancer","display_name":"advanced epithelial ovarian cancer","score":0.984000027179718},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.734000027179718},{"id":"https://openalex.org/keywords/postoperative-treatment","display_name":"postoperative treatment","score":0.675000011920929},{"id":"https://openalex.org/keywords/brca-mutations","display_name":"BRCA mutations","score":0.6399999856948853},{"id":"https://openalex.org/keywords/homologous-recombination-deficiency","display_name":"homologous recombination deficiency","score":0.996999979019165},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.9309999942779541},{"id":"https://openalex.org/keywords/chemosensitivity","display_name":"chemosensitivity","score":0.6970000267028809},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.796999990940094},{"id":"https://openalex.org/keywords/individualized-treatment-decision-making","display_name":"individualized treatment decision-making","score":0.6779999732971191},{"id":"https://openalex.org/keywords/clinical-decision-pathway","display_name":"clinical decision pathway","score":0.8659999966621399}],"concepts":[{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.9527000188827515},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8526999950408936},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6539000272750854},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.5418000221252441},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5317999720573425},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4763999879360199},{"id":"https://openalex.org/C2779974597","wikidata":"https://www.wikidata.org/wiki/Q28448986","display_name":"Clinical Practice","level":2,"score":0.4749000072479248},{"id":"https://openalex.org/C2780673598","wikidata":"https://www.wikidata.org/wiki/Q285223","display_name":"Genetic testing","level":2,"score":0.45910000801086426},{"id":"https://openalex.org/C2992773878","wikidata":"https://www.wikidata.org/wiki/Q7645976","display_name":"Epithelial ovarian cancer","level":4,"score":0.43779999017715454},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.3621000051498413},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.3472000062465668},{"id":"https://openalex.org/C163763905","wikidata":"https://www.wikidata.org/wiki/Q17075943","display_name":"Precision medicine","level":2,"score":0.3366999924182892},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.31940001249313354},{"id":"https://openalex.org/C3020404979","wikidata":"https://www.wikidata.org/wiki/Q1058438","display_name":"Risk stratification","level":2,"score":0.31150001287460327},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.30730000138282776},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.2897000014781952},{"id":"https://openalex.org/C32220436","wikidata":"https://www.wikidata.org/wiki/Q2072214","display_name":"Personalized medicine","level":2,"score":0.26969999074935913},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.2689000070095062}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.3389/fphar.2026.1931140","doi":"https://doi.org/10.3389/fphar.2026.1931140","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1931140","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1931140/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.3389/fphar.2026.1931140","doi":"https://doi.org/10.3389/fphar.2026.1931140","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1931140","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1931140/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225618145.pdf","grobid_xml":"https://content.openalex.org/works/W7225618145.grobid-xml"},"referenced_works_count":25,"referenced_works":["https://openalex.org/W2088050133","https://openalex.org/W2102306754","https://openalex.org/W2111900617","https://openalex.org/W2135947389","https://openalex.org/W2399195235","https://openalex.org/W2583998975","https://openalex.org/W2772338061","https://openalex.org/W2897430921","https://openalex.org/W2951714360","https://openalex.org/W2994977341","https://openalex.org/W4211051419","https://openalex.org/W4295078726","https://openalex.org/W4306661079","https://openalex.org/W4377115689","https://openalex.org/W4385951392","https://openalex.org/W4390078374","https://openalex.org/W4399901732","https://openalex.org/W4410310272","https://openalex.org/W4412594477","https://openalex.org/W4416291497","https://openalex.org/W4416673826","https://openalex.org/W4417465677","https://openalex.org/W7120160145","https://openalex.org/W7122830163","https://openalex.org/W7154009115"],"related_works":["https://openalex.org/W4392633122","https://openalex.org/W4306661079","https://openalex.org/W4281697296","https://openalex.org/W3014984749","https://openalex.org/W7220858228","https://openalex.org/W4409613320","https://openalex.org/W4389953889","https://openalex.org/W3028607434","https://openalex.org/W4392634330","https://openalex.org/W4403746293"],"abstract_inverted_index":{"Bevacizumab":[0],"is":[1,177],"an":[2,181],"important":[3],"component":[4],"of":[5,17,31,68,75,105,189],"first-line":[6,135,192],"therapy":[7],"for":[8,113,185],"advanced":[9,193],"epithelial":[10],"ovarian":[11,194],"cancer;":[12],"however,":[13,107],"the":[14,29,48,66,84,89,102,144,186],"precise":[15],"identification":[16],"patients":[18,125],"who":[19],"will":[20],"benefit":[21],"and":[22,54,153,162],"how":[23],"to":[24,179],"optimize":[25],"its":[26],"use":[27,188],"in":[28,41,78,191],"era":[30],"poly":[32],"(ADP-ribose)":[33],"polymerase":[34],"inhibitors":[35],"(PARPi)":[36],"remains":[37],"a":[38,62,72,127,150,166],"core":[39],"challenge":[40],"clinical":[42,121,167],"practice.":[43],"This":[44,147],"review":[45,148],"systematically":[46],"revisits":[47],"pivotal":[49],"phase":[50],"III":[51],"trials":[52],"GOG-0218":[53],"ICON7,":[55],"together":[56],"with":[57,61,126,174],"their":[58],"inherent":[59],"limitations,":[60],"particular":[63],"focus":[64],"on":[65,83,158],"role":[67],"KELIM":[69,172],"score":[70],"as":[71],"dynamic":[73],"marker":[74],"chemotherapy":[76],"sensitivity":[77],"predicting":[79],"bevacizumab":[80,133,138,190],"efficacy.":[81],"Based":[82],"interaction":[85],"test":[86],"from":[87],"GOG-0218,":[88],"available":[90,159],"evidence":[91,161],"suggests":[92],"that":[93,170],"BRCA/homologous":[94],"recombination":[95],"deficiency":[96],"(HRD)":[97],"status":[98],"does":[99],"not":[100],"alter":[101],"single-agent":[103],"activity":[104],"bevacizumab;":[106],"these":[108],"genetic":[109],"markers":[110],"remain":[111],"crucial":[112],"guiding":[114],"PARPi":[115],"or":[116,141],"combination":[117],"regimens.":[118],"A":[119],"key":[120],"dilemma":[122],"arises":[123],"when":[124],"BRCA":[128],"mutation":[129],"have":[130],"already":[131],"received":[132],"during":[134,143],"chemotherapy:":[136],"should":[137],"be":[139],"continued":[140],"discontinued":[142],"maintenance":[145],"phase?":[146],"presents":[149],"preference":[151],"analysis":[152],"individualized":[154],"decision-making":[155],"factors":[156],"based":[157],"indirect":[160],"current":[163],"guidelines.":[164],"Finally,":[165],"decision":[168],"pathway":[169],"integrates":[171],"assessment":[173],"HRD":[175],"testing":[176],"proposed":[178],"provide":[180],"evidence-based":[182],"reference":[183],"framework":[184],"rational":[187],"cancer.":[195]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-10T00:00:00"}